Local application of tacrolimus in distal colitis: Feasible and safe

Inflammatory Bowel Diseases

Volumn 15, Issue 2, 2009, Pages 193-198

  van Dieren, Jolanda M ^a   van Bodegraven, Ad A ^b   Kuipers, Ernst J ^a   Bakker, Eke N ^b   Poen, Alexander C ^c   van Dekken, Herman ^a   Nieuwenhuis, Edward E S ^a   van der Woude, C Janneke ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

Author keywords

Colitis; Enema; Suppository; Tacrolimus; Treatment

Indexed keywords

AZATHIOPRINE; ENEMA; GLUCOSE; MESALAZINE; METHOTREXATE; STEROID; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; SUPPOSITORY; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; COLITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RECURRENCE; SUPPOSITORIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 67649695583     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20644     Document Type: Article

References (16)

1. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
2. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994;106:1429-1435.
3. Brynskov J, Freund L, Thomsen OO, et al. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet. 1989; 1:721-722.
4. Ranzi T, Campanini MC, Velio P, et al. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet. 1989;2:97.
5. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol. 1993;88:640-645.
6. van Dieren JM, Kuipers EJ, Samsom JN, et al. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis. 2006;12:311-327.
7. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:1273-1281.
8. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr. 2000;137:794-799.
9. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002;8:317-324.
10. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003;18:415- 423.
11. Ogata H, Matsui T, Nakamura M, et al. A randomised, dose-finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-1262.
12. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
13. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000; 47:404-409.
14. Arya R, Grossie VB Jr, Weisbrodt NW, et al. Temporal expression of tumor necrosis factor-alpha and nitric oxide synthase 2 in rat small intestine after endotoxin. Dig Dis Sci. 2000;45:744-749.
15. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
16. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996;62:900-905.